Effects of an Industrial Hemp-Based Nutraceutical on Post-Operative TPLO Pain

Nov 12, 2019

*NOTE: Enrollment is closed for this study*

Study Objective

The use of cannabinoid derivatives in the treatment of a variety of neurological disorders in humans has recently been explored, particularly in the treatment of chronic pain and epilepsy. Full spectrum cannabinoid rich industrial hemp-based nutraceuticals (HBN) below 0.3% THC have been shown to have no psychotropic effects and modest activity through non-cannabinoid receptor routes affecting the serotonergic, glycinergic and GABA neurotransmission pathways that may be able to diminish pain, as well as inflammation.

Some patients will receive a placebo and regular pain medication post surgery. The other patients will get the hemp-derived nutraceutical in addition to the regular pain medication.

Eligibility Requirements:

  • Dog undergoing TPLO surgery
  • Owner must sign consent form
  • Owner must agree to complete canine brief inventory of pain and Helsinki scale scores for their dog

Owner Incentive:

Owner is responsible for surgery and all costs associated. The study charges are covered by the Sponsor.


Garrett Davis, DVM, DACVS
Jason Tarricone, DVM, Resident in Small Animal Surgery
Surgery Department

Red Bank Veterinary Hospital
197 Hance Ave, Tinton Falls, NJ 07724
(732) 747-3636

See All Clinical Studies